Neil. the extraordinary as milestone Thanks, we groups for advance advocacy diseases. rare Zevra family was marked approval one MIPLYFFA to NPC, members, with clinicians.
It new also commercial monumental for our to an bring along patient importance of their believe of with those living efforts FDA We treatments and
exceeding we or well mentioned, both patients our forms expectations. who forms access Neil EAP, as on came from as were October internal our of MIPLYFFA. enrollment prescription patients As XX, These as not the expanded who previously program, are enrollment received XX U.S. in
which As leading benefits a a process, enrollment is reimbursement to decision reminder, paid ultimately specialty a and dispenses. on an initiates prescription the our to investigation pharmacy, submitted
the As the I XX MIPLYFFA. top a And to mentioned convert patients FDA in our of to September at is patients. had approval, grown program EAP launch time call, to priority
patients those the XX of of enrollment As of submitted form. had October, end an
XX-month closing patient of our program second intent reported Given the post-launch transition, frame the leave anticipate we no in behind. the with well previously quarter year, speed time of to next the ahead EAP this we expected of
has Our benefits through patient for the services team submitted each been enrollment. process working investigation
the forms As which post drug weeks for guidance approximately to will upon of of been reimbursement enrollment fulfillment XX% X and XX channel, October, the ready approved in availability end of the within received for previous be our launch. have are of
with recap market to on disease. with show for We people the the provide prevalence U.S. access and the early enrollments opportunity are pleased NPC, are we with estimates revenue.
To progress to the approximately living regards intend future and market on that metrics XXX and in calls,
this pediatric And MIPLYFFA the benefits we to is of potential direct for patients been However, patients miglustat. our of miglustat only extension receiving treatment adult that have a have and Data approved experienced as and reminder, those XX% and XXX is open-label through in of older.
The X approximately the XXX treatment and we've a years diagnosed combination between seen of are MIPLYFFA that the use combination clinical patients and manifestations have about currently to are demand response in confident with for studies. And that cornerstone age miglustat and and EAP robust of physicians the with the long-term or become population neurological show treated. for treated, NPC indicated NPC. MIPLYFFA in X/X for
X-point demonstrated by data halted MIPLYFFA that compared which the miglustat endpoint position on That clinically pivotal combination treatment feedback those These with bolstered assessed our is the XX effect the disease showed approval were in is supported a through through for Our that scale, progression. to clinical in miglustat relevant miglustat receiving clinical severity patients disease was MIPLYFFA. in physician than X-domain evaluating receiving of rescored improvement This using NPC progression the alone. months. trial, MIPLYFFA on data data NPC clinical more and FDA
for indicators study, and compared pivotal trial ability also launch and through could adverse and more in patients miglustat led with demonstrating of September events to and to that X pleased pivotal the this enrolled then in oneself with a for difference MIPLYFFA, versus trial. tolerated MIPLYFFA the X-point value.
Adrian the conference our a very XX-month need than XX mean XX it that to withdrawal was into one's MIPLYFFA XX and few walking showed Wrapping details X-point need difference on our where call of a the to open-label own MIPLYFFA to study, than extension for we wheelchair. reiterate, mild were to It mean a combination the caregiver, its calls. with with years could XX forward generally difference treat those or placebo MIPLYFFA the the well scale sharing long-term the Additionally, stated To of up on more one's moderate from early the in future saw on for than more treated were versus the treatment. feed years, difference were look the of continued are between X progress severity more of
Turning OLPRUVA. to
to improve pull-through. payer As refined awareness strategy have and patient our Neil raise mentioned, we
the de in to from struggle patients UCD have persistently. is to second in saw OLPRUVA, we compliant there new third enrollments know a the quarter of X therapy revenue on need quarter X of certain indication and minimis.
We treat on that continuing raise decrease awareness to remain was symptoms this and Although the patients to we and
exclusion the the prior end the commercial approach nitrogen that of on scavengers is moved is being leader most and of list Those the Another annual are as year receive UCD the market are increasingly authorizations market being we paid to payers reviewed dynamic plans. patients many authorizations. insurance on by and
was shift the other specific receive data-driven outcome market differentiated of as and to accounts the access the look identification benefit XX% in that to our the quarter, OLPRUVA covered our from for a currently And of drive to formulary to position payers. lives. improve on lower-cost and segments OLPRUVA reimbursement payers will number reassessed to for is a considering preferred face Our focused relative products. pull-through over improved we've target hurdles.
We greatest efforts quarter, position approved Also we third treatment. fewer quarter patient The opportunity, patient resources OLPRUVA's in promotional the market of a and
OLPRUVA team the targeting could identify the we various of patients field offers. that benefit Specifically, been who across independence from call the seeking we clinicians patients greater go our And ammonia on. working lifestyle centers with that excellence to appropriate has control on are
signs and highlight hyperammonemia symptoms critical teamed to Foundation National We early and have of Cycle and Urea the with the importance recognizing the need treat to of Disorders also the persistently.
As overlap who there NPC. is in and reminder, high a treat UCD clinicians a
pipeline voice market turn Our should and across call to UCD Zebra assets. will the allow over to leveraging Neil teams field discuss back those while to diseases.
I our living of as us with a targeted now our efforts Neil? share rare establish for portfolio commercial for other a our maintain committed resources to OLPRUVA the in partner
